Find Oncology Drugs in Phase III Clinical Development in SWITZERLAND

Lead Product(s): Atezolizumab,Bevacizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe & effective treatments are available to patients.

Lead Product(s): Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy didn’t hit its primary endpoint in muscle-invasive urothelial cancer. The primary endpoint was disease-free survival.

Lead Product(s): Galinpepimut-S,Pembrolizumab,Nivolumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway